secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001376339-26-000032
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q1 net sales $59M (-33% YoY), loss $11M; cuts FY guidance to $260-290M
-----------------------------------------------------------------------------

- Q1 net sales $59M, down 33% YoY from $88M; net loss $11M vs net income $7M a year ago.
- Surgical product sales up 13% YoY; Wound sales down 60% due to Medicare payment cap per cm².
- Gross margin fell to 71% from 81% on pricing pressure and unfavorable product mix.
- FY2026 net sales guidance lowered to $260-290M; Adjusted EBITDA expected approximately breakeven.
- Company plans $40M annualized cost savings; CEO targets return to profitability in H2 and double-digit growth in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000137633926000032/0001376339-26-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000137633926000032/mdxg-20260429.htm
  HTML page:      https://secwatch.observer/filing/0001376339-26-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer